Real World Experience with Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center

Keyphrases

• Older Adults 100%
• Tertiary Care 100%
• Real-world Experience 100%
• Pediatric Inflammatory Bowel Disease 100%
• Ustekinumab 100%
• Disease Activity 42%
• Tumor Necrosis Factor-α 28%
• Inflammatory Bowel Disease 28%
• Crohn's Disease 28%
• Nave 28%
• Treatment-free Remission 28%
• Pediatric Patients 14%
• Serious Adverse Events 14%
• Serious Infection 14%
• Safety Outcomes 14%
• Ulcerative Colitis 14%
• Pediatric Population 14%
• Clinical Characteristics 14%
• Univariate Analysis 14%
• Age Groups 14%
• Effective Treatment 14%
• Disease Location 14%
• Mayo Score 14%
• Clinical Trial Data 14%
• Descriptive Statistics 14%
• Treatment History 14%
• Surgical History 14%
• Observational Cohort Study 14%
• Harvey-Bradshaw Index 14%
• Outcome Analysis 14%
• Off-label Use 14%
• Patient-initiated 14%
• Infusion Reaction 14%
• Activity History 14%
• Efficacy Outcomes 14%
• Controlled Clinical Trial 14%
• Vedolizumab 14%

Medicine and Dentistry

• Tertiary Care 100%
• Pediatrics 100%
• Ustekinumab 100%
• Inflammatory Bowel Disease 100%
• Tumor Necrosis Factor 28%
• Crohn's Disease 28%
• Steroid 28%
• Pediatrics Patient 14%
• Infection 14%
• Ulcerative Colitis 14%
• Infusion 14%
• Patient with Inflammatory Bowel Disease 14%
• Disease Activity 14%
• Vedolizumab 14%
• Controlled Clinical Trial 14%
• Univariate Analysis 14%
• Surgical History 14%
• Off-Label Use 14%
• Age Groups 14%
• Diseases 14%
• Cohort Studies 14%
• Adverse Event 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Ustekinumab 100%
• Tumor Necrosis Factor 28%
• Remission 28%
• Crohn's Disease 28%
• Steroids 28%
• Adverse Event 14%
• Infection 14%
• Disease Activity 14%
• Vedolizumab 14%
• Ulcerative Colitis 14%
• Cohort Study 14%
• Controlled Clinical Trial 14%
• Off-Label Use 14%
• Diseases 14%